Echocardiographic Outcomes With Transcatheter Edge-to-Edge Repair for Degenerative Mitral Regurgitation in Prohibitive Surgical Risk Patients. JACC. Cardiovascular imaging Marcoff, L., Koulogiannis, K., Aldaia, L., Mediratta, A., Chadderdon, S. M., Makar, M. M., Ruf, T. F., Gößler, T., Zaroff, J. G., Leung, G. K., Ku, I. A., Nabauer, M., Grayburn, P. A., Wang, Z., Hawthorne, K. M., Fowler, D. E., Dal-Bianco, J. P., Vannan, M. A., Bevilacqua, C., Meineri, M., Ender, J., Forner, A. F., Puthumana, J. J., Mansoor, A. H., Lloyd, D. J., Voskanian, S. J., Ghobrial, A., Hahn, R. T., Mahmood, F., Haeffele, C., Ong, G., Schneider, L. M., Wang, D. D., Sekaran, N. K., Koss, E., Mehla, P., Harb, S., Miyasaka, R., Ivannikova, M., Stewart-Dehner, T., Mitchel, L., Raissi, S. R., Kalbacher, D., Biswas, S., Ho, E. C., Goldberg, Y., Smith, R. L., Hausleiter, J., Lim, D. S., Gillam, L. D. 2023


The CLASP IID randomized trial (Edwards PASCAL TrAnScatheter Valve RePair System Pivotal Clinical Trial; NCT03706833) demonstrated the safety and effectiveness of the PASCAL system for mitral transcatheter edge-to-edge repair (M-TEER) in patients at prohibitive surgical risk with significant symptomatic degenerative mitral regurgitation (DMR).This study describes the echocardiographic methods and outcomes from the CLASP IID trial and analyzes baseline variables associated with residual mitral regurgitation (MR) =1+.An independent echocardiographic core laboratory assessed echocardiographic parameters based on American Society of Echocardiography guidelines focusing on MR mechanism, severity, and feasibility of M-TEER. Factors associated with residual MR =1+ were identified using logistic regression.In 180 randomized patients, baseline echocardiographic parameters were well matched between the PASCAL (n = 117) and MitraClip (n = 63) groups, with flail leaflets present in 79.2% of patients. Baseline MR was 4+ in 76.4% and 3+ in 23.6% of patients. All patients achieved MR =2+ at discharge. The proportion of patients with MR =1+ was similar in both groups at discharge but diverged at 6 months, favoring PASCAL (83.7% vs 71.2%). Overall, patients with a smaller flail gap were significantly more likely to achieve MR =1+ at discharge (adjusted OR: 0.70; 95% CI: 0.50-0.99). Patients treated with PASCAL and those with a smaller flail gap were significantly more likely to sustain MR =1+ to 6 months (adjusted OR: 2.72 and 0.76; 95% CI: 1.08-6.89 and 0.60-0.98, respectively).The study used DMR-specific echocardiographic methodology for M-TEER reflecting current guidelines and advances in 3-dimensional echocardiography. Treatment with PASCAL and a smaller flail gap were significant factors in sustaining MR =1+ to 6 months. Results demonstrate that MR =1+ is an achievable benchmark for successful M-TEER. (Edwards PASCAL TrAnScatheter Valve RePair System Pivotal Clinical Trial [CLASP IID]; NCT03706833).

View details for DOI 10.1016/j.jcmg.2023.09.015

View details for PubMedID 38099912